Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARADIGM study of mFOLFOX6 + panitumumab versus mFOLFOX6 + bevacizumab in chemotherapy-naive RAS wild-type metastatic colorectal cancer
jRCTs031180246Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of panitumumab, bevacizumab, oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by Takeda. Primary endpoint: Overall survival. Started May 2015; status: completed.
02
Drugs
panitumumabbevacizumaboxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031180246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180246.